All lobbying filings

AKIN GUMP STRAUSS HAUER & FELD

Lobbying for BIOTECHNOLOGY INNOVATION ORGANIZATION

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 2

HR 1262
Mikaela Naylon Give Kids a Chance Act
S 3302
Mikaela Naylon Give Kids a Chance Act of 2025

Lobbying activity 2

Small Business

Issues related to the Small Business Innovation Research Program in the Small Business Innovation and Economic Security Act (P.L. 119-83).

Health Issues

Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.